N-benzyl-2,7-dimethylimidazo[1,2-a]pyridine-3-carboxamide | 1282522-64-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: N-benzyl-2,7-dimethylimidazo[1,2-a]pyridine-3-carboxamide
• 英文别名: IDR-0106898；ND-008454；N-benzyl-2,7-dimethyl-imidazo[1,2-a]pyridine-3-carboxamide
• CAS: 1282522-64-8
• 化学式: C₁₇H₁₇N₃O
• 分子量: 279.341
• InChiKey: URVCVNNBOXIDES-UHFFFAOYSA-N

物化性质

• 密度：
  1.18±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  46.4
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2,7-二甲基咪唑并[1,2-a]吡啶-3-羧酸乙酯 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 lithium hydroxide 作用下， 以 乙醇 、 乙腈 为溶剂， 反应 12.0h， 生成 N-benzyl-2,7-dimethylimidazo[1,2-a]pyridine-3-carboxamide
  参考文献：
  名称：

  Advancement of Imidazo[1,2-a]pyridines with Improved Pharmacokinetics and nM Activity vs. Mycobacterium tuberculosis

  摘要：

  A set of 14 imidazo[1,2-a]pyridine-3-carboxamides was synthesized and screened against Mycobacterium tuberculosis H(37)Rv. The minimum inhibitory concentrations of 12 of these agents were <= 1 mu M against replicating bacteria and 5 compounds (9, 12, 16, 17, and 18) had MIC values <= 0.006 mu M. Compounds 13 and 18 were screened against a panel of MDR and XDR drug resistant clinical Mtb strains with the potency of 18 surpassing that of clinical candidate PA-824 by nearly 10-fold. The in vivo pharmacokinetics of compounds 13 and 18 were evaluated in male mice by oral (PO) and intravenous (IV) routes. These results indicate that readily synthesized imidazo[1,2-a]pyridine-3-carboxamides are an exciting new class of potent, selective anti-TB agents that merit additional development opportunities.

  DOI：

  10.1021/ml400088y

文献信息

• Anti-Inflammation Compounds
  申请人：No Zaesung

  公开号：US20140155387A1

  公开（公告）日：2014-06-05

  The present invention refers to: a compound having the general formula (I), wherein n is 0, 1, 2 or; m is 0, 1, 2 or 3; o is 0, 1, 2 or 3; W, X, Y and Z are independently selected from CH, N or N-oxide; A is NR 4 , C═O, C═S, OP(O)(O), P═O, CH 2 , or a heteroarly selected from the group consisting of (a), (b), (c), (d), (e), (f), (g); V is C═O, O, S, CH 2 , or NR 5 ; as well as its use in treating inflammatory diseases such as asthma, COPD, inflammation post infection, arthritis, atherosclerosis, pain and dermatitis.

  本发明涉及一种具有通式（I）的化合物，其中n为0、1、2或；m为0、1、2或3；o为0、1、2或3；W、X、Y和Z分别独立地选自CH、N或N-氧化物；A为NR4、C═O、C═S、OP(O)(O)、P═O、CH2，或从（a）、（b）、（c）、（d）、（e）、（f）、（g）组成的群体中选择的杂环基；V为C═O、O、S、CH2或NR5；以及其在治疗哮喘、COPD、感染后炎症、关节炎、动脉粥样硬化、疼痛和皮炎等炎症性疾病中的用途。
• IMIDAZO [1,2-a]PYRIDINE COMPOUNDS, SYNTHESIS THEREOF, AND METHODS OF USING SAME
  申请人：Miller Marvin J.

  公开号：US20120220457A1

  公开（公告）日：2012-08-30

  Embodiments relate to the field of chemistry and biochemistry, and, more specifically, to imidazopyridine compounds, synthesis thereof, and methods of using same. Disclosed herein are various imidazo[1,2-a]pyhdine compounds and methods of using the novel compounds to treat or prevent tuberculosis in a subject or to inhibit fungal growth on plant species. Other embodiments include methods of synthesizing imidazo [1,2- a]pyridine compounds, such as the disclosed imidazo[1,2-a]pyridine compounds.

  本实施例涉及化学和生物化学领域，更具体地涉及咪唑吡啶化合物，其合成以及使用方法。本文公开了各种咪唑[1,2-a]吡啶化合物，以及使用这些新型化合物治疗或预防主体的结核病或抑制植物物种上的真菌生长的方法。其他实施例包括合成咪唑[1,2-a]吡啶化合物的方法，例如公开的咪唑[1,2-a]吡啶化合物。
• Imidazo [1,2-a]pyridine compounds, synthesis thereof, and methods of using same
  申请人：UNIVERSITY OF NOTRE DAME DU LAC

  公开号：US10913737B2

  公开（公告）日：2021-02-09

  Embodiments relate to the field of chemistry and biochemistry, and, more specifically, to imidazopyridine compounds, synthesis thereof, and methods of using same. Disclosed herein are various imidazo[1,2-a]pyhdine compounds and methods of using the novel compounds to treat or prevent tuberculosis in a subject or to inhibit fungal growth on plant species. Other embodiments include methods of synthesizing imidazo[1,2-a]pyridine compounds, such as the disclosed imidazo[1,2-a]pyridine compounds.

  本发明实施例涉及化学和生物化学领域，更具体地说，涉及咪唑并吡啶化合物、其合成及其使用方法。本文公开了各种咪唑并[1,2-a]吡啶化合物以及使用这些新型化合物治疗或预防受试者的结核病或抑制植物上真菌生长的方法。其他实施方案包括合成咪唑并[1,2-a]吡啶化合物的方法，例如所公开的咪唑并[1,2-a]吡啶化合物。
• Generation and exploration of new classes of antitubercular agents: The optimization of oxazolines, oxazoles, thiazolines, thiazoles to imidazo[1,2-a]pyridines and isomeric 5,6-fused scaffolds
  作者：Garrett C. Moraski、Lowell D. Markley、Mayland Chang、Sanghyun Cho、Scott G. Franzblau、Chang Hwa Hwang、Helena Boshoff、Marvin J. Miller

  DOI：10.1016/j.bmc.2012.02.025

  日期：2012.4

  Tuberculosis (TB) is a devastating disease resulting in a death every 20 s. Thus, new drugs are urgently needed. Herein we report ten classes of compounds-oxazoline, oxazole, thiazoline, thiazole, pyrazole, pyridine, isoxazole,imidazo[1,2-a] pyridine, imidazo[1,2-a] pyrimidine and imidazo[1,2-c] pyrimidine-which have good (micromolar) to excellent (sub-micromolar) antitubercular potency. The 5,6-fused heteroaromatic compounds were the most potent with MIC's as low as < 0.195 mu M (9 and 11). Overall, the imidazo[1,2-a] pyridine class was determined to be most promising, with potency similar to isoniazid and PA-824 against replicating Mtb H(37)Rv, clinically relevant drug sensitive, multi-and extensively resistant Mtb strains as well as having good in vitro metabolic stability. (C) 2012 Elsevier Ltd. All rights reserved.
• Scaffold-switching: An exploration of 5,6-fused bicyclic heteroaromatics systems to afford antituberculosis activity akin to the imidazo[1,2-a]pyridine-3-carboxylates
  作者：Garrett C. Moraski、Allen G. Oliver、Lowell D. Markley、Sanghyun Cho、Scott G. Franzblau、Marvin J. Miller

  DOI：10.1016/j.bmcl.2014.05.062

  日期：2014.8

  A set of 5,6-fused bicyclic heteroaromatic scaffolds were investigated for their in vitro anti-tubercular activity versus replicating and non-replicating strains of Mycobacterium tuberculosis (Mtb) in an attempt to find an alternative scaffold to the imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrimidines that were previously shown to have potent activity against replicating and drug resistant Mtb. The five new bicyclic heteroaromatic scaffolds explored in this study include a 2,6-dimethylimidazo[1,2-b]pyridazine-3-carboxamide (7), a 2,6-dimethyl-1H-indole-3-carboxamide (8), a 6-methyl-1H-indazole-3-carboxamide (9), a 7-methyl-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide (10), and a 5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carboxamide (11). Additionally, imidazo[1,2-a]pyridines isomers (2 and 12) and a homologous imidazo[1,2-a]pyrimidine isomer (6) were prepared and compared. Compounds 2 and 6 were found to be the most potent against H(37)Rv Mtb (MIC's of 0.1 mu M and 1.3 mu M) and were inactive (MIC >128 mu M) against Staphylococcus aureus, Escherichia coli and Candida albicans. Against other non-tubercular mycobacteria strains, compounds 2 and 6 had activity against Mycobacterium avium (16 and 122 mu M, respectively), Mycobacterium kansasii (4 and 19 mu M, respectively), Mycobacterium bovis BCG (1 and 8 mu M, respectively) while all the other scaffolds were inactive (>128 mu M). (C) 2014 Elsevier Ltd. All rights reserved.